ProCE Banner Activity

Next-Generation BTK Inhibitors and Why We Need Them

Clinical Thought
With 2 BTK inhibitors currently approved for various hematologic malignancies, I will discuss the rationale and importance of continuing to develop additional agents in this class and what we hope to achieve.

Released: October 24, 2019

Expiration: October 22, 2020

No longer available for credit.

Share

Faculty

John Pagel

John Pagel, MD, PhD

Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene Ltd

Loxo Oncology subsidiary of Eli Lilly

Faculty Disclosure

Primary Author

John Pagel, MD, PhD

Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

John Pagel, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Gilead Sciences, and Pharmacyclics.